Mental health status of varenicline and bupropion users during a quit attempt compared to current smokers, other quitters, and non-smokers

Drug and Alcohol Dependence

Volumn 154, Issue , 2015, Pages 132-138

  Shewale, Anand R ^a   Borse, Mrudula S ^b   Brown, Joshua D ^a,c   Li, Chenghui ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Bupropion; Depression; Mental health; Psychiatric disturbances; Varenicline

Indexed keywords

AMFEBUTAMONE; VARENICLINE; NICOTINIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASSESSMENT OF HUMANS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE SEVERITY; DISTRESS SYNDROME; FEMALE; HEALTH INSURANCE; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; KESSLER 6 SCALE; MAJOR CLINICAL STUDY; MALE; MENTAL COMPONENT SUMMARY; MENTAL HEALTH; MIDDLE AGED; MISCELLANEOUS NAMED GROUPS; NON SMOKER; OTHER QUITTER; OUTCOME ASSESSMENT; PATIENT HEALTH QUESTIONNAIRE; PREVALENCE; PRIORITY JOURNAL; SELF REPORT; SENSITIVITY ANALYSIS; SHORT FORM 12; SMOKING; SMOKING CESSATION; YOUNG ADULT; ADOLESCENT; CHEMICALLY INDUCED; COMPLICATION; MENTAL DISORDERS; PSYCHOLOGY; UNITED STATES;

ADOLESCENT; ADULT; AGED; BUPROPION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NICOTINIC AGONISTS; SMOKING; SMOKING CESSATION; UNITED STATES; VARENICLINE; YOUNG ADULT;

EID: 84938979153     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.06.028     Document Type: Article

References (47)

1. Adams C.E., Tull M.T., Gratz K.L. The role of emotional nonacceptance in the relation between depression and recent cigarette smoking. Am. J. Addict. 2012, 4:293-301.
2. Agaku I.T., King B.A., Dube S.R. Current cigarette smoking among adults-United States, 2005-2012. MMWR 2014, 63:29-34. Centers for Disease Control and Prevention (CDC).
3. Bolton J.M., Robinson J. Population-attributable fractions of Axis I and Axis II mental disorders for suicide attempts: findings from a representative sample of the adult, noninstitutionalized US population. Am. J. Public Health 2010, 100:2473-2480.
4. Cahill K., Stevens S., Perera R., Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst. Rev. 2013, 5:CD009329.
5. Cerimele J.M., Durango A. Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder?. A review of published studies. J. Clin. Psychiatry 2012, 73:1039-1047.
6. Dhelaria R.K., Friderici J., Wu K., Gupta E., Khan C., Rothberg M.B. Effectiveness of varenicline for smoking cessation at 2 urban academic health centers. Eur. J. Intern. Med. 2012, 23:461-464.
7. Duaso M., Duncan D. Health impact of smoking and smoking cessation strategies: current evidence. Br. J. Community Nurs. 2012, 17:356-363.
8. Etter J.F., Schneider N.G. An internet survey of use, opinions and preferences for smoking cessation medications: nicotine, varenicline, and bupropion. Nicotine Tob. Res. 2013, 15:59-68.
9. Gandek B., Ware J.E., Aaronson N.K., Apolone G., Bjorner J.B., Brazier J.E., Bullinger M., Kaasa S., Leplege A., Prieto L., Sullivan M. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J. Clin. Epidemiol. 1998, 51:1171-1178.
10. Gibbons R.D., Mann J.J. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am. J. Psychiatry 2013, 170:1460-1467.
11. Glassman A.H., Covey L.S., Stetner F., Rivelli S. Smoking cessation and the course of major depression: a follow-up study. Lancet 2001, 357:1929-1932.
12. Gunnell D., Irvine D., Wise L., Davies C., Martin R.M. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009, 339:b3805.
13. Hajek P., Stead L.F., West R., Jarvis M., Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database Syst. Rev. 2009, 1:CD003999.
14. Hayford K.E., Patten C.A., Rummans T.A., Schroeder D.R., Offord K.P., Croghan I.T., Glover E.D., Sachs D.P., Hurt R.D. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br. J. Psychiatry 1999, 174:173-178.
15. Herman A.I., Sofuoglu M. Comparison of available treatments for tobacco addiction. Curr. Psychiatry Rep. 2010, 12:433-440.
16. Hill S.C., Roemer M., Stagnitti M.N. Outpatient Prescription Drugs: Data Collection and Editing in the 2011 Medical Expenditure Panel Survey. Methodology Report 29 2014, Agency for Healthcare Research and Quality, Rockville, MD.
17. Hope A.A., Kumanyika S.K., Shults J., Holmes W.C. Changes in health-related quality of life among African-Americans in a lifestyle weight loss program. Qual. Life Res. 2010, 19:1025-1033.
18. Hsueh S.C., Hsueh K.C., Chou M.Y., Tu M.S. A comparison of the effectiveness of varenicline and transdermal nicotine patch in outpatients following a standardized smoking cessation program in Southern Taiwan. Eval. Health Prof. 2012, 38:115-125.
19. Hughes J.R., Stead L.F., Hartmann-Boyce J., Cahill K., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst. Rev. 2014, (1):CD000031.
20. Hughes J.R. Varenicline as a cause of suicidal outcomes. Nicotine Tob. Res. 2015, ntu275 [pii].
21. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., Smith S.S., Muramoto M.L., Daughton D.M., Doan K., Fiore M.C., Baker T.B. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 1999, 340:685-691.
22. Kessler R.C., Barker P.R., Colpe L.J., Epstein J.F., Gfroerer J.C., Hiripi E., Howes M.J., Normand S.L., Manderscheid R.W., Walters E.E., Zaslavsky A.M. Screening for serious mental illness in the general population. Arch. Gen. Psychiatry 2003, 60:184-189.
23. Kotz D., Brown J., West R. Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: evidence from an English population study. Psychopharmacology 2014, 231:37-42.
24. Kroenke K., Spitzer R.L., Williams J.B. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med. Care 2003, 41:1284-1292.
25. Kumar S., Kodela S., Detweiler J.G., Kim K.Y., Detweiler M.B. Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature. Gen. Hosp. Psychiatry 2011, 33:612-617.
26. Leventhal A.M., Ameringer K.J., Osborn E., Zvolensky M.J., Langdon K.J. Anxiety and depressive symptoms and affective patterns of tobacco withdrawal. Drug Alcohol Depend. 2013, 133:324-329.
27. Lorenz R.A., Whitley H.P., McCoy E.K. Safety of varenicline in patients with mental illness. Prim. Psychiatry 2010, 9:17.
28. Lowe B., Kroenke K., Grafe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). J. Psychosom. Res. 2005, 58:163-171.
29. McClure J.B., Swan G.E., Catz S.L., Jack L., Javitz H., McAfee T., Deprey M., Richards J., Zbikowski S.M. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J. Subst. Abuse Treat. 2010, 38:394-402.
30. McNeil J.J., Piccenna L., Ioannides-Demos L.L. Smoking cessation-recent advances. Cardiovasc. Drugs Ther. 2010, 24:359-367.
31. Mendelsohn C. Smoking and depression-a review. Aust. Fam. Physician 2012, 41:304-307.
32. Meyer T.E., Taylor L.G., Xie S., Graham D.J., Mosholder A.D., Williams J.R., Moeny D., Ouellet-Hellstrom R.P., Coster T.S. Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction 2013, 108:203-210.
33. Miller M., Hemenway D., Rimm E. Cigarettes and suicide: a prospective study of 50,000 men. Am. J. Public Health 2000, 90:768-773.
34. Mills E.J., Wu P., Lockhart I., Thorlund K., Puhan M., Ebbert J.O. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann. Med. 2012, 44:588-597.
35. Montazeri A., Vahdaninia M., Mousavi S.J., Asadi-Lari M., Omidvari S., Tavousi M. The 12-item medical outcomes study short form health survey version 2.0 (SF-12v2): a population-based validation study from Tehran, Iran. Health Qual. Life Outcomes 2011, 9:12.
36. Pierce J.P., Gilpin E.A. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002, 288:1260-1264.
37. Rahman S., Alexanderson K., Jokinen J., Mittendorfer-Rutz E. Risk factors for suicidal behaviour in individuals on disability pension due to common mental disorders-a nationwide register-based prospective cohort study in Sweden. PLoS ONE 2014, 9:e98497.
38. Sicras M.A., Navarro A.R., Diaz C.S., Marti S.B., Sanz D.B.V. Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care. Aten. Primaria 2011, 43:482-489.
39. Smith S.S., Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Jamerson B., Fiore M.C., Baker T.B. Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine Tob. Res. 2003, 5:99-109.
40. Stabèl M. Predictors of Success at the Smoking Cessation Outpatient Clinic at Medisch Spectrum Twente 2009, UT, Netherlands.
41. US FDA Drug Safety Information for Healthcare Professionals. Information for Healthcare Professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics) 2013, US FDA, Available: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169986.htm (2014,8/14/2014).
42. USDHHS The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General 2014, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, Available: http://ash.org/wpcontent/uploads/2014/01/full-report.pdf (2014, 8/13/2014).
43. Veldhuizen S., Cairney J., Kurdyak P., Streiner D.L. The sensitivity of the K6 as a screen for any disorder in community mental health surveys: a cautionary note. Can. J. Psychiatry 2007, 52:256-259.
44. Von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P., Strobe Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev. Med. 2007, 45:247-251.
45. Ward B.W., Schiller J.S., Goodman R.A. Multiple chronic conditions among US adults: a 2012 update. Prev. Chronic Dis. 2014, 11:E62.
46. Woolacott N.F., Jones L., Forbes C.A., Mather L.C., Sowden A.J., Song F.J., Raftery J.P., Aveyard P.N., Hyde C.J., Barton P.M. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol. Assess. 2002, 6:1-245.
47. Zhu S.H., Sun J., Billings S.C., Choi W.S., Malarcher A. Predictors of smoking cessation in U.S. adolescents. Am. J. Prev. Med. 1999, 16:202-207.